- Home
- / RAPT Therapeutics
RAPT Therapeutics
Stock Price
$2
2024-10-29
Market Capitalization
$69.8 M
2024-10-29
Revenue
$1.5 M
FY, 2022
RAPT Therapeutics Summary
Company Summary
- Overview
- RAPT Therapeutics (also known as FLX Bio) is a biopharmaceutical company that develops and commercializes immuno-oncology agents. The company is focused on developing molecule drugs which activate the immune system to eradicate cancer. Rapt Therapeutics also elaborates novel therapies to prolong the lives of people with cancer.
- Type
- Public
- Status
- Active
- Founded
- 2015
- HQ
- South San Francisco, CA, US | view all locations
- Website
- https://www.rapt.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Rodney Young, Chief Financial Officer
Brian Wong, President and Chief Executive Officer, Director
David Wustrow, Senior Vice President, Drug Discovery and Preclinical Development
LocationsView all
1 location detected
South San Francisco, CA HQ
United States
561 Eccles Ave
RAPT Therapeutics Financials
Summary Financials
- Net income (Q3, 2025)
- ($17.6M)
- Cash (Q3, 2025)
- $37.9M
- EBIT (Q3, 2025)
- ($19.4M)
- Enterprise value
- $34.5M